Portland, ORNCT05780034Now EnrollingIRB Ready

Relapsed/Refractory B-cell Malignancies Clinical Trial in Portland, OR

Access cutting-edge relapsed/refractory b-cell malignancies treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by Accutar Biotechnology Inc

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access relapsed/refractory b-cell malignancies specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed/refractory b-cell malignancies treatment provided free

Apply for This Portland Location

Check if you qualify for this relapsed/refractory b-cell malignancies clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Relapsed/Refractory B-cell Malignancies Study in Portland

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676

Sponsor: Accutar Biotechnology Inc

Who Can Participate

Inclusion Criteria

Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF).
Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).
Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Investigator or who are not amenable (intolerability, patient choice) to standard therapies.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:
Treatment with any of the following:
Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days).
Systemic chemotherapy within 14 days.
Radiation therapy within 14 days
Biologics (Antibodies) treatment within 28 days,
Radioimmunoconjugates or toxin conjugates within 12 weeks.
Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.
History of central nervous system lymphoma/leukemia in remission for less than 2 years.
Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT05780034) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed/Refractory B-cell Malignancies Treatment Options in Portland, OR

If you're searching for relapsed/refractory b-cell malignancies treatment options in Portland, OR, this clinical trial (NCT05780034) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed/refractory b-cell malignancies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed/refractory b-cell malignancies clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Portland, OR

See all rheumatoid arthritis clinical trials recruiting in Portland — not just this study.

Browse Rheumatoid Arthritis Trials in Portland →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR